Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Preclinical targeting of B-cell lymphoma using the humanized monoclonal antibody CMC-544

Feb. 2, 2005

Northwest to begin phase III trial of DCVax-Prostate

Feb. 2, 2005

Tarvacin cleared to enter new phase I study

Feb. 1, 2005

Treatment begins in phase II study of HER-2 Protein AutoVac

Jan. 28, 2005

AMD-3100 phase III program opens enrollment

Jan. 28, 2005

Viventia completes enrollment in second phase I study of Proxinium

Jan. 28, 2005

Good safety profile reported for CEA-TRICOM vaccines in advanced cancer patients

Jan. 25, 2005

VRPs expressing HER2/neu prevent breast cancer growth and tumorigenesis in mice

Jan. 24, 2005

Additional phase III Ceplene study in AML required by FDA

Jan. 20, 2005

Abgenix to receive milestone payment from Chiron for oncology antibody

Jan. 18, 2005

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 11, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026